- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02579252
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease (ADAMANT)
A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease.
60% of participants will receive AADvac1 and 40% of participants will receive placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder of the brain. Over the course of the disease, pathological proteins accumulate in the brain, damaging neurons, thus causing them to lose their connections and die.
Currently available treatments are designed to compensate for the neurotransmitter loss caused by the disease without affecting the disease process itself.
AADvac1 is designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These antibodies are expected to prevent tau protein from aggregating, to facilitate the removal of tau protein aggregates and prevent the spreading of pathology, slowing or halting the progress of the disease.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Niederosterreich
-
Horn, Niederosterreich, Austria, 3580
- Ordination Dr. Bancher
-
-
Steiermark
-
Graz, Steiermark, Austria, 8036
- Universitätsklinik für Neurologie
-
-
Tirol
-
Hall in Tirol, Tirol, Austria, 6060
- Abteilung Psychiatrie und Psychotherapie, LKH Hall
-
Innsbruck, Tirol, Austria, 6020
- Universitätsklinikum Innsbruck
-
-
-
-
-
Brno, Czechia, 656 91
- Fakultni nemocnice u sv. Anny v Brne, Mezinarodni centrum klinickeho vyzkumu (ICRC), Centrum pro kognitivni poruchy, Neuro 2
-
Hradec Kralove, Czechia, 500 05
- Fakultní nemocnice Hradec Králové, Neurologická klinika
-
Klecany, Czechia, 250 67
- Narodni ustav dusevniho zdravi (NÚDZ), Department of cognitive disorders - AD Center
-
Praha, Czechia, 128 21
- Vseobecna Fakultni Nemocnice V Praze
-
Praha, Czechia, 150 06
- Fakultni nemocnice v Motole
-
-
-
-
-
Mannheim, Germany, 68159
- Universität Heidelberg, Zentralinstitut für Seelische Gesundheit
-
München, Germany, 81675
- Klinikum rechts der Isar der Technischen Universität München, Klinik und Poliklinik fur Psychiatrie und Psychotherapie
-
Nürnberg, Germany, 90402
- Praxis Dr. Klaus Christian Steinwachs
-
Ulm, Germany, 89081
- Universitätsklinikum Ulm, Klinik und Poliklinik für Neurologie
-
-
Rheinland-Pfalz
-
Erbach, Rheinland-Pfalz, Germany, 64711
- Neuro Centrum Odenwald
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04107
- Arzneimittelforschung Leipzig (AFL)
-
-
-
-
-
Bialystok, Poland, 15-756
- Podlaskie Centrum Psychogeriatrii
-
Bydgoszcz, Poland, 85-796
- Pallmed prowadzacy NZOZ Dom Sue Ryder w Bydgoszczy Centrum Psychoneurologii Wieku Podeszlego
-
Katowice, Poland, 40-123
- Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
-
Katowice, Poland, 40-752
- Care Clinic
-
Kraków, Poland, 31-505
- Centrum Neurologii Klinicznej, Krakowska Akademia Neurologii
-
Lublin, Poland, 20-362
- KO-MED Centra Kliniczne Sp. z o.o.
-
Olsztyn, Poland, 10-082
- Oddzial Neurologiczny
-
Poznan, Poland, 61-853
- NZOZ Neuro-Kard
-
Szczecin, Poland, 70-111
- Euromedis Sp. z o.o.
-
Warszawa, Poland, 01-697
- Centrum Medyczne NeuroProtect
-
Wroclaw, Poland, 53-139
- Wrocławskie Centrum Alzheimerowskie
-
-
-
-
-
Bucharest, Romania, 030447
- "Dr. Constantin Gorgos" Psychiatry Hospital Titan
-
-
-
-
-
Banska Bystrica, Slovakia, 974 04
- Neurologická ambulancia
-
Bratislava, Slovakia, 81107
- Nestatna psychiatricka ambulancia
-
Bratislava, Slovakia, 813 69
- Univerzitna nemocnica Bratislava, Nemocnica Stare Mesto, I. Neurologicka klinika LF UK a UNB
-
Bratislava, Slovakia, 81369
- Univerzitna nemocnica Bratislava, Psychiatricka klinika LFUK a UNB
-
Kosice, Slovakia, 041 90
- Univerzitna nemocnica L Pasteura Kosice, Psychiatricka klinika
-
Krompachy, Slovakia, 05342
- NEURES, s.r.o. Neurologicka ambulancia
-
Svidnik, Slovakia, 089 01
- Centrum zdravia R.B.K., s.r.o., Psychiatricka ambulancia
-
Trencin, Slovakia, 91108
- Pro Mente Sana S.R.O., Psychiatricka Ambulancia
-
Zilina, Slovakia, 012 07
- Fakultna nemocnica s poliklinikou Zilina, Psychiatricke oddelenie
-
-
-
-
-
Ljubljana, Slovenia, 1000
- Univerzitetni klinični Center Ljubljana, Neurology Clinic
-
Maribor, Slovenia, 2000
- University Clinical Centre Maribor
-
-
-
-
-
Malmö, Sweden, SE-20502
- Skånes Universitetssjukhus Malmö, Minneskliniken
-
Mölndal, Sweden, SE-43141
- Sahlgrenska Universitetssjukhuset, Minnesmottagningen
-
Stockholm, Sweden, SE-14186
- Karolinska Universitetssjukhuset Huddinge
-
Uppsala, Sweden, SE-75185
- Akademiska Sjukhuset I Uppsala, Minnes-och geriatrikmottagningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria (abbreviated):
- Diagnosis of probable Alzheimer's disease according to the revised National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (McKhann 2011).
- Mini Mental State Examination (MMSE) score ≥ 20 and ≤ 26.
- Brain MRI finding consistent with the diagnosis of Alzheimer's disease
- Medial temporal lobe atrophy: Scheltens score of ≥ 2 (on a scale of 0-4 on the more atrophied side) AND/OR positive AD biomarker profile in the CSF (amyloid+, tau+)
- At least 6 years of formal elementary education.
- Age 50-85 years.
- Fluency in the local language and sufficient auditory and visual capacities to allow neuropsychological testing.
- Ability to read and understand the informed consent.
- Stable therapy with an acetylcholinesterase inhibitor for at least 3 months prior to screening.
- If the patient is on memantine treatment, the dose regimen must be stable for at least 3 months prior to screening.
- Hachinski Ischemia Scale score ≤ 4.
- Availability of a caregiver.
- Female patients must be either surgically sterile or at least 2 years postmenopausal.
- Male patients must either be surgically sterile, or he and his female spouse/partner who is of childbearing potential must be using highly effective contraception starting at screening and continuing throughout the study period.
- Patient provides written informed consent.
Exclusion criteria (abbreviated):
- Participation in another clinical study within 3 months prior to screening.
- Pregnant or breastfeeding female.
- Not expected to complete the clinical study.
- Known allergy to components of the vaccine.
- Contraindication for MRI imaging.
Any of the following detected by brain MRI:
- Infarction in the territory of large vessels
- More than one lacunar infarct.
- Any lacunar infarct in a strategically important location.
- Confluent hemispheric deep white matter lesions (Fazekas grade 3).
- Other focal lesions which may be responsible for the cognitive status of the patient or any other abnormalities associated with significant central nervous disease other than Alzheimer's disease.
- Surgery (under general anaesthesia) within 3 months prior to screening and/or scheduled surgery (under general anaesthesia) during the whole study period.
- Patient has a history and/or currently suffers from a clinically significant autoimmune disease, or is expected to receive immunosuppressive or immunomodulatory treatment at the present or in the future.
- Recent history of cancer (last specific treatment ≤ 5 years prior to Screening).
- Myocardial infarction within 2 years prior to screening.
- Hepatitis B, C, HIV or Syphilis.
- Active infectious disease.
- Presence and/or history of immunodeficiency.
Patient currently suffering from a clinically important systemic illness:
- poorly controlled congestive heart failure (NYHA ≥ 3)
- BMI > 40
- poorly controlled diabetes (HbA1c > 7.5%)
- severe renal insufficiency (eGFR < 30 mL/min)
- chronic liver disease - ALT (alanine aminotransferase) > 66 U/L in females or > 80 U/L in males, AST (aspartate aminotransferase) > 82 U/L
- QTc interval prolongation in ECG (> 450 ms)
- other clinically significant systemic illness, if considered relevant by the investigator
- Hypothyroidism, defined as TSH (thyroid-stimulating hormone) elevation > 5.000 mcIU/mL, and/or FT4 levels < 0.7 ng/dL. Patients with corrected hypothyroidism are eligible for the study provided that treatment has been stable for 3 months before study entry.
- Valid diagnosis of a significant psychiatric illness such as schizophrenia, any type of psychotic disorder or bipolar affective disorder.
- Current depressive episode (Geriatric Depression Scale GDS ≥ 6) or major depressive episode within the last 1 years.
- Metabolic or toxic encephalopathy or dementia due to a general medical condition.
- History of alcohol or drug abuse or dependence within the past 2 years.
- Wernicke's encephalopathy.
- History or evidence of any CNS disorder other than AD that could be the cause of dementia.
- Cerebrovascular disease (ischemic or haemorrhagic stroke), or diagnosis of possible, probable or definite vascular dementia.
- Epilepsy.
- Treatment with experimental immunotherapeutics including intravenous immunoglobulin within 3 months prior to screening.
- Treatment with experimental therapies for AD aiming at disease-modification within 3 months prior to screening.
- Patient is currently being treated or was treated in the past with any active vaccines for AD.
- Treatment with immunosuppressive drugs.
- Change in dose of previous and current medications within the last 30 days prior to Screening (V01), if considered clinically relevant by the investigator.
- Vitamin B12 deficiency (serum vitamin B12 < 191 pg/mL).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AADvac1
AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses. |
|
Placebo Comparator: Placebo
Placebo is a suspension for subcutaneous injection.
Placebo is provided in single-use vials.
Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer.
Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (all-case treatment-emergent adverse events except local reactions)
Time Frame: 24 months
|
The safety and tolerability of AADvac1 in the treatment of patients with mild Alzheimer disease, as assessed by AEs, vital signs, ECG, laboratory measures, MRI of the brain, physical and neurological examination, Columbia Suicide Severity Rating Scale (C-SSRS) and review of the Patient Diary
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Dementia Rating (CDR) Sum of Boxes
Time Frame: 24 months
|
The domain scores of the standard 6-domain CDR assessment will be summed up to obtain a Sum-of-Boxes score of 0-18
|
24 months
|
Custom cognitive battery (composite standard score)
Time Frame: 24 months
|
A composite standard score will be calculated from the following tests: Cogstate International Shopping List Task (memory)
Cogstate One Card Learning Task (memory) Cogstate One Card Back Task (memory) Category Fluency Test (executive function, language) Letter Fluency Test (executive function, language) Digit Symbol Coding (executive functioning, working memory and processing speed) |
24 months
|
Alzheimer's Disease Cooperative Study - Activities of Daily Living questionnaire (version for Mild Cognitive Impairment) (ADCS MCI ADL)
Time Frame: 24 months
|
Activities of daily living will be assessed using the informant-based ADCS questionnaire (both the score for the 18-point and the 24-point version will be calculated)
|
24 months
|
Immunogenicity
Time Frame: 24 months
|
24 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Exploratory: Fludeoxyglucose Positron Emission Tomography (FDG PET) assessment of brain metabolism (change in cerebral glucose metabolic rate expressed as Standardised Uptake Value Ratio [SUVR] change, multiple regions of interest)
Time Frame: 24 months
|
24 months
|
Exploratory: MRI volumetry
Time Frame: 24 months
|
24 months
|
Exploratory: Cerebrospinal fluid (CSF) biomarkers
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Reinhold Schmidt, Prof. MD., Medical University, Graz, Austria
Publications and helpful links
General Publications
- Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther. 2014 Aug 1;6(4):45. doi: 10.1186/alzrt277. eCollection 2014.
- Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014 Aug 1;6(4):44. doi: 10.1186/alzrt278. eCollection 2014.
- Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smisek M, Sivak R, Winblad B, Novak M. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017 Feb;16(2):123-134. doi: 10.1016/S1474-4422(16)30331-3. Epub 2016 Dec 10.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-AD-003
- 2015-000630-30 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States